Iaso Therapeutics Inc.
East Lansing, MI Iaso Therapeutics, Inc.
- UEI
- DXLWUB84NJJ5
- CAGE
- 82ER3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4942 Dawn Ave #108, East Lansing, MI 48823, USA
- Website
- iasotherapeutics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Next generation multi-antigen staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage qbeta -… | National Institute of Allergy and Infectious Diseases | $599,998 | |
| Sbir phase II: a novel bacteriophage mutant as a platform carrier for next generation vaccines -the broader… | National Science Foundation | $1,366,595 | |
| Development of proprietary bacteriophage qbeta as a vaccine carrier platform for anti-salmonella vaccine - project… | National Institute of Allergy and Infectious Diseases | $1,489,124 | |
| A novel vaccine strategy to target breast cancer enabled by proprietary mutant bacteriophage qbeta-tumor antigen… | National Cancer Institute | $300,000 | |
| Sbir phase i: development of bacteriophage qbeta and mutants as carriers for next generation vaccines | Division of Industrial Innovation | $225,000 |
About Iaso Therapeutics Inc.
Iaso Therapeutics Inc. is a biotechnology company focused on developing novel technologies for next generation vaccines targeting cancer and infectious diseases. The company specializes in creating conjugate vaccines using proprietary bacteriophage mutants as immunogenic carrier platforms to enhance immune response against weakly immunogenic subunit antigens.
Through various prime and sub federal grants from the National Institutes of Health, National Science Foundation, and National Cancer Institute, Iaso Therapeutics Inc. has conducted research and development to establish robust protocols for expressing, purifying and storing its proprietary bacteriophage mutant MQSS virus-like particle at scale for use as a vaccine carrier. The company has performed comparative studies demonstrating MQSS's ability to elicit higher antibody levels compared to benchmark carriers. Iaso Therapeutics has also applied the MQSS platform to deliver Salmonella-associated glycans to develop pre-clinical data supporting anti-Salmonella vaccines protecting against multiple pathogenic strains. Additionally, the company is developing MQSS-tumor antigen conjugates as a novel vaccine strategy targeting breast cancer.
Quick answers
What is Iaso Therapeutics Inc.'s UEI?
Iaso Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is DXLWUB84NJJ5.
What is Iaso Therapeutics Inc.'s CAGE code?
Iaso Therapeutics Inc.'s CAGE code is 82ER3.
What is Iaso Therapeutics Inc.'s primary NAICS code?
Iaso Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Iaso Therapeutics Inc. located?
Iaso Therapeutics Inc.'s physical address in SAM.gov is 4942 Dawn Ave #108, East Lansing, MI 48823, USA.
Is Iaso Therapeutics Inc. registered in SAM.gov?
Yes. Iaso Therapeutics Inc.'s SAM.gov registration is active through May 8, 2027.
What is Iaso Therapeutics Inc.'s most recent federal award?
Iaso Therapeutics Inc.'s most recent federal grant award is Next generation multi-antigen staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage qbeta -… (R43AI197624), from National Institute of Allergy and Infectious Diseases, on July 1, 2026.
On GovTribe
See Iaso Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors